Key Predictors of Mild Cognitive Impairment in Type 2 Diabetes Mellitus and Their Interacting Mechanisms: A Narrative Review from a Network Analysis Perspective - Top-Institutions - MDSpire

Key Predictors of Mild Cognitive Impairment in Type 2 Diabetes Mellitus and Their Interacting Mechanisms: A Narrative Review from a Network Analysis Perspective

  • By

  • Qiongqiong Sun

  • LingYan Zhang

  • Jianwen Zhao

  • Shanshan Wang

  • April 29, 2026

  • 0 min

Share

Top Institutions in Endocrinology

Brief introduction explaining scope and methodology.

  • #1

    Joslin Diabetes Center
    Joslin Diabetes Center

    Boston, MA

    Key Differentiators

    • Endocrinology
    • Diabetes Research
    • Neurology

  • #2

    Mayo Clinic
    Mayo Clinic

    Rochester, MN

    Key Differentiators

    • Neurology
    • Endocrinology
    • Geriatrics

  • #3

    University of California, San Francisco (UCSF)
    University of California, San Francisco (UCSF)

    San Francisco, CA

    Key Differentiators

    • Neurology
    • Endocrinology
    • Neuroscience

  • #4

    Massachusetts General Hospital (MGH)
    Massachusetts General Hospital (MGH)

    Boston, MA

    Key Differentiators

    • Neurology
    • Endocrinology
    • Geriatrics

  • #5

    Peking University Health Science Center
    Peking University Health Science Center

    Beijing, Beijing

    Key Differentiators

    • Endocrinology
    • Neurology
    • Geriatrics

Original Source(s)

Key Predictors of Mild Cognitive Impairment in Type 2 Diabetes Mellitus and Their Interacting Mechanisms: A Narrative Review from a Network Analysis Perspective

  • by Qiongqiong Sun, LingYan Zhang, Jianwen Zhao, Shanshan Wang

  • April 29, 2026

Related Content

AACE 2026: AI moves from hype to reality in diabetes care

"Right now, AI is more of a copilot, but the long-term vision is something much closer to autopilot."

Diabetic Retinal Disease Rates Narrow by Diabetes Type

US claims data showed rising prevalence of diabetic retinal disease in type 1 and type 2 diabetes, while incidence declined in type 1 diabetes and moved closer to type 2 rates by 2022.

Loss of REST associated with Alzheimer's disease pathology is ameliorated by NAD+